About: SARS-Coronavirus-2 nucleocapsid protein measured in blood using a Simoa ultra-sensitive immunoassay differentiates COVID-19 infection with high clinical sensitivity.

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: SARS-Coronavirus-2 nucleocapsid protein measured in blood using a Simoa ultra-sensitive immunoassay differentiates COVID-19 infection with high clinical sensitivity. Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	SARS-Coronavirus-2 nucleocapsid protein measured in blood using a Simoa ultra-sensitive immunoassay differentiates COVID-19 infection with high clinical sensitivity.
Creator	Zhang, Ying Ball, Andrew Wilson, David Chang, Lei Kaiser, Kim Latz, Eicke Beauregard, Katie Burke, Elaine Cleary, Megan Fernandes, Syrena Holdridge, Marcella Hrusovsky, Kevin Johnson, Joseph Mattoon, Dawn Mendes, Muriel Natterman, Jacob Patel, Purvish Plavina, Tatiana Schmidt, Susanne Shan, Dandan Suib, Hannah Xu, Samantha Yao, Xiao
Source	MedRxiv
abstract	The COVID-19 pandemic continues to have an unprecedented impact on societies and economies worldwide. Despite rapid advances in diagnostic test development and scale-up, there remains an ongoing need for SARS-CoV-2 tests which are highly sensitive, specific, minimally invasive, cost-effective and scalable for broad testing and surveillance. Here we report development of a highly sensitive single molecule array (Simoa) immunoassay on the automated HD-X platform for the detection of SARS-CoV-2 Nucleocapsid protein (N-protein) in venous and capillary blood (fingerstick). In pre-pandemic and clinical sample sets, the assay has 100% specificity and 97.4% sensitivity for serum / plasma samples. The limit of detection (LoD) estimated by titration of inactivated SARS-CoV-2 virus is 0.2 pg/ml, corresponding to 0.05 Median Tissue Culture Infectious Dose (TCID50) per ml, > 2000 times more sensitive than current EUA approved antigen tests. No cross-reactivity to other common respiratory viruses, including hCoV229E, hCoVOC43, hCoVNL63, Influenza A or Influenza B, was observed. We detected elevated N-protein concentrations in symptomatic, asymptomatic, and pre-symptomatic PCR+ individuals using capillary blood from a finger-stick collection device. The Simoa SARS-CoV-2 N-protein assay has the potential to detect COVID-19 infection via antigen in blood with similar or better performance characteristics of molecular tests, while also enabling at home and point of care sample collection.
has issue date	2020-08-17(xsd:dateTime)
bibo:doi	10.1101/2020.08.14.20175356
has license	medrxiv
sha1sum (hex)	7a069d606ef94f6added5d1fb1f14c7cb2087aa2
schema:url	https://doi.org/10.1101/2020.08.14.20175356
resource representing a document's title	SARS-Coronavirus-2 nucleocapsid protein measured in blood using a Simoa ultra-sensitive immunoassay differentiates COVID-19 infection with high clinical sensitivity.
resource representing a document's body	covid:7a069d606ef94f6added5d1fb1f14c7cb2087aa2#body_text
is schema:about of	named entity 'impact' named entity 'COVID-19' named entity 'Summary' named entity 'IMMUNOASSAY' named entity 'ONGOING' named entity 'SPECIFIC' named entity 'BROAD' named entity 'testing' named entity 'specific' named entity 'immunoassay' named entity 'plasma' named entity 'measured' named entity 'protein' named entity 'minimally invasive' named entity 'immunoassay' named entity 'SARS' named entity 'asymptomatic' named entity 'COVID-19 infection' named entity 'immunoassay' named entity 'preprint' named entity 'protein' named entity 'SARS-CoV2' named entity 'False negative' named entity 'antigen' named entity 'preprint' named entity 'enzyme' named entity 'preprint' named entity 'symptom' named entity 'antibody' named entity 'clinical symptoms' named entity 'medRxiv' named entity 'pathogens' named entity 'antigen' named entity 'protein' named entity 'Influenza' named entity 'peer review' named entity 'infection' named entity 'blood samples' named entity 'heart attack' named entity 'infection' named entity 'symptom' named entity 'antigens' named entity 'protein' named entity 'false negative results' named entity 'IgG' named entity 'molecular testing' named entity 'signal loss' named entity 'M. pneumoniae' named entity 'antigen' named entity 'Legionella' named entity 'COVID-19 pandemic' named entity 'preprint' named entity 'antigen' named entity 'medRxiv' named entity 'antigen' named entity 'capillary blood' named entity 'virus' named entity 'preprint' named entity 'antigen' named entity 'seroconversion' named entity 'RT-PCR' named entity 'Serum' named entity 'COVID'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software